Inhibition of the DNA damage response to activate immune responses toward tumors.

IF 5.5 2区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

FEBS Journal Pub Date : 2021-08-01 Epub Date: 2021-04-02 DOI:10.1111/febs.15836

Sheetal Sharma, Mrinal Srivastava

引用次数: 0

Abstract

Cancer immunotherapy represents a very encouraging mode of treatment for cancer where one's immune system is utilized to eliminate tumor cells. Wayne et al. explore inhibition of DNA damage response (DDR) pathways with small molecule inhibitors as a means to prime cells with immune response. These findings suggest that a one-size-fits-all approach cannot be used when harnessing immune response via DDR inhibitors and genotoxic agents, which are required ultimately for the success of immunotherapy. Comment on: https://doi.org/10.1111/febs.15747.

查看原文本刊更多论文

抑制DNA损伤反应以激活对肿瘤的免疫反应。

癌症免疫疗法是一种非常令人鼓舞的癌症治疗模式，利用免疫系统来消除肿瘤细胞。Wayne等人探索用小分子抑制剂抑制DNA损伤反应(DDR)途径，作为引发免疫反应的细胞的一种手段。这些发现表明，当通过DDR抑制剂和基因毒性药物利用免疫反应时，不能使用一刀切的方法，这是免疫治疗成功的最终要求。评论:https://doi.org/10.1111/febs.15747。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

FEBS Journal 生物-生化与分子生物学

CiteScore

11.70

自引率

1.90%

发文量

375

审稿时长

1 months

期刊介绍： The FEBS Journal is an international journal devoted to the rapid publication of full-length papers covering a wide range of topics in any area of the molecular life sciences. The criteria for acceptance are originality and high quality research, which will provide novel perspectives in a specific area of research, and will be of interest to our broad readership. The journal does not accept papers that describe the expression of specific genes and proteins or test the effect of a drug or reagent, without presenting any biological significance. Papers describing bioinformatics, modelling or structural studies of specific systems or molecules should include experimental data.